NJ-LABVANTAGE-SOLUTIONS
25.4.2022 14:02:07 CEST | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Forensic NavigatorTM , an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005012/en/
Forensic Navigator handles data flows in real time, from the evidence gathered at the crime scene through the ultimate resolution of the investigation. It accelerates the investigative process by streamlining, connecting, and analyzing all aspects of a criminal case, including evidence collection, property management, forensic lab analyses, medical examiner processes and reports, investigative activities, and legal proceedings. Forensic Navigator also includes critical tools to ensure quality management and regulatory compliance, in addition to forensic intelligence capabilities that allow users to gain insight from all data generated spanning investigations even across cases.
“LabVantage Forensic Navigator is a breakthrough informatics platform designed to increase the efficiency, effectiveness and accuracy of criminal justice operations,” said Mikael Hagstroem, Chief Executive Officer of LabVantage Solutions. “Forensic Navigator is built on the foundation of our industry-leading LIMS platform, but our developers went beyond those capabilities to produce a comprehensive system capable of managing and integrating the enormous amount of information generated during criminal investigations. At LabVantage we aim to bring the benefits of digital transformation to a variety of data-intensive industries, and we are proud to introduce this important new product purpose-built for the criminal justice sector, where data abounds and the stakes are so high.”
Forensic Navigator uses browser-based technology that is cloud hosted and is available in either SaaS or on-premise formats. It is a single, integrated, configurable platform that eliminates the need for customization. Forensic Navigator supports compliance with ISO17025, CALEA and other accreditations. It encompasses the entire forensic life cycle with best-in-class cybersecurity protection. Forensic Navigator’s forensics intelligence software provides insights from investigative data and is enhanced by predictive analysis through its forensic intelligence capabilities.
Robin MacDonald, PhD, Senior Product Specialist at LabVantage, spent more than a decade managing a forensic unit serving one of the largest counties in Florida. Dr. MacDonald noted, “The comprehensive data management capabilities of LabVantage Forensic Navigator would have been a huge help when I was a front-line forensic scientist at a busy law enforcement agency. In the complex, highly regulated criminal justice environment, Forensic Navigator’s ability to seamlessly manage all the evidence and data needed for investigations is a major advantage, eliminating the burden and inefficiency of implementing, maintaining, and coordinating multiple data management systems. It allows law enforcement personnel to enter data in real time, make examination requests and check status from a secure web-based portal. We offer a go-live plan that simplifies implementation and LabVantage’s track record of exceptional customer service means that expert user support is always available.”
Key advantages of LabVantage Forensic Navigator include:
- Advanced technology - HTML5-based platform with advanced predictive analytics via forensic intelligence.
- Browser-based - Cloud hosted and available in either SaaS or on-premise formats.
- Configurable - With industry best practices, including data integrity and cybersecurity protection.
- Online portal - For evidence pre-log, exam requests, status updates, and released reports.
- Dashboards - View all key performance indicators at a glance.
- Instruments - Integration and interface with most networkable instruments.
- Collaboration - Enables rapid access to shared data. Duplicative entry is never needed.
- Chain of custody - Includes person-to-person and person-to-secure-location transfers, with reporting options.
- Case management – Facilitates organizing all aspects of the case.
- Crime scene – Upload images and videos, capture scene-processing activities, and generate reports.
- Property management – Easily locate evidence and manage disposition activities.
- Medical examiner - Document external and autopsy observations, track next-of-kin, capture interviews.
- Laboratory – Track evidence through intake, examination assignment, testing, and reporting.
- Electronic lab notebook - Tracking support throughout the entire analytical life cycle.
- Reagents - Manage reagents, standards, and other laboratory consumables.
- Forensic intelligence - Pool siloed data for rapid resolution of cases and confidence in results.
- SDMS - Collect and secure files maintained throughout the lab with full traceability and search functions.
For more information on LabVantage Forensic Navigator click here or email info@labvantage.com .
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005012/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
